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Abstract
The maintenance of normal body weight is disrupted in patients with anorexia nervosa (AN) for 
prolonged periods of time. Prior to the onset of AN, premorbid body mass index (BMI) spans the 
entire range from underweight to obese. After recovery, patients have reduced rates of overweight 
and obesity. As such, loci involved in body weight regulation may also be relevant for AN and vice 
versa. Our primary analysis comprised a cross-trait analysis of the 1000 single nucleotide 
polymorphisms (SNPs) with the lowest p-values in a genome-wide association meta-analysis 
(GWAMA) of AN (GCAN) for evidence of association in the largest published GWAMA for BMI 
(GIANT). Subsequently we performed sex-stratified analyses for these 1000 SNPs. Functional ex 
vivo studies on four genes ensued. Lastly, a look-up of GWAMA-derived BMI related loci was 
performed in the AN GWAMA. We detected significant associations (p-values < 5×10−5, 
Bonferroni corrected p < 0.05) for 9 SNP alleles at 3 independent loci. Interestingly, all AN 
susceptibility alleles were consistently associated with increased BMI. None of the genes (chr. 10: 
CTBP2, chr. 19: CCNE1, chr. 2: CARF and NBEAL1; the latter is a region with high linkage 
disequilibrium) nearest to these SNPs has previously been associated with AN or obesity. Sex-
stratified analyses revealed that the strongest BMI signal originated predominantly from females 
(chr. 10 rs1561589; poverall: 2.47 × 10−06/pfemales: 3.45 × 10−07/pmales: 0.043). Functional ex vivo 
studies in mice revealed reduced hypothalamic expression of Ctbp2 and Nbeal1 after fasting. 
Hypothalamic expression of Ctbp2 was increased in diet induced obese (DIO) mice as compared 
to age-matched lean controls. We observed no evidence for associations for the look-up of BMI 
related loci in the AN GWAMA. A cross-trait analysis of AN and BMI loci revealed variants at 
three chromosomal loci with potential joint impact. The chromosome 10 locus is particularly 
promising given that the association with obesity was primarily driven by females. In addition, the 
detected altered hypothalamic expression patterns of Ctbp2 and Nbeal1 as a result of fasting and 
DIO implicate these genes in weight regulation.
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Introduction
The joint analysis of GWAS data pertaining to different phenotypes/diseases with 
overlapping or co-morbid endophenotypes recently led to the discovery of novel genes that 
had escaped detection in single phenotype/disease analyses. For instance, by a cross-disorder 
analysis of five major psychiatric disorders common underlying biological mechanisms were 
revealed1,2. A number of genetic variants were associated with more than one psychiatric 
disorder, illustrating the usefulness of the approach. Other cross-disorder analyses have 
shown overlapping genetic risk factors for phenotypes that had not been expected to share 
risk factors (e.g., ulcerative colitis and bone density or white blood cell count3). Heritability 
of anorexia nervosa (AN) is moderately high4–8. However, the two published GWAMA9,10 
were underpowered to detect signals of small effect sizes, which are characteristic of SNPs 
identified for other psychiatric disorders1,2. The largest GWAMA for AN was performed in 
2,907 patients with AN and 14,860 controls by the Genetic Consortium for AN (GCAN) and 
the Wellcome Trust Case Control Consortium 3 (WTCCC3). Although a global meta-
analysis comprised discovery and replication data sets on a total of 5,551 AN cases and 
21,080 controls, genome-wide significance was not reached10. However, 76% of the variant 
effects were directionally consistent between discovery and replication groups. This 
observation was unlikely to be spurious (p = 4 × 10−6)10.
A substantial genetic contribution to the variance of body mass index (BMI) is implicated by 
twin, family, and adoption studies11,12. The largest currently published GWAMA pertaining 
to BMI variance revealed 97 genome-wide significant (p ≤ 5×10−08) gene loci13; we use the 
term ‘BMI SNPs’ for those SNPs associated with an increased BMI. As most of the 
respective genes are expressed in the brain, a largely central regulation of human body 
weight appears likely13,14. A region on chromosome 16p11.2 supports a possible genetic 
link between obesity and AN. Carriers of the respective deletion(s) are hyperphagic and 
obese, whereas the carriers of the duplication(s) are underweight and show restrictive/
selective eating behavior15,16.
Sex-specific analyses have previously been conducted for BMI and related phenotypes. For 
instance, the weight increasing effect was more pronounced in female mice of the initial 
melano-cortin-4 receptor gene (Mc4r) knock-out strain17. In humans with MC4R mutations 
leading to reduced function, the weight increasing effect was also stronger in females18. 
Sex-stratified GWAMAs for waist-hip ratio variation and other anthropometric traits (height, 
weight, body mass index, waist circumference, and hip circumference) revealed a sexual 
dimorphism in the genetic effects for fat distribution and waist phenotypes19–22. For many of 
these, genome-wide significance was detected for females only19,20.
AN might be considered as an extreme weight condition23, potentially entailing that genetic 
factors involved in body weight regulation may overlap with those predisposing to AN as 
suggested by several groups8,10,23–30. Recent LD-score regression analyses revealed a 
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negative genetic correlation between AN and obesity (and a similar genetic correlation with 
BMI) suggesting that the same genetic factors influence normal variation in BMI as well as 
dysregulated BMI in AN30. However, in the latest GWAMA for AN 89 SNPs with genome-
wide significance for BMI variation and obesity31,32 and 15 SNPs related to extreme 
obesity31 were not associated with AN10.
There is no evidence for an aberrant body weight regulation prior to manifestation of AN; 
thus, recalled premorbid weight of AN patients seemingly covers the whole BMI range33–35. 
The BMI range of patients at medium term (five to ten years) follow-ups is shifted to the left 
(lower BMI); in recovered patients overweight occurs with a substantially lower probability 
than in the general population36,37.
Here we performed three cross-trait analyses involving AN risk and BMI variation in two 
GWAMAs. First, we performed a cross-trait analysis of the 1000 SNPs with the lowest p-
values from the largest GWAMA for AN (GCAN10) for evidence of association in the 
largest published GWAMA for BMI variation (GIANT13). Second, we performed sensitivity 
analyses in sex-stratified data sets from the BMI GWAMA for the best cross-trait SNPs 
(Table 1) because of the profound female preponderance in AN38,39; furthermore, sex-
stratified analyses have revealed BMI loci that had not been detected in sex-combined 
analyses13. Finally, we performed a look-up of GWAMA derived BMI, (childhood) obesity 
and waist-hip ratio (WHR) loci within the AN GWAMA.
Post hoc we also performed (1) a look-up of the best cross-trait SNPs (Table 1) in: (1) obese 
children and adolescents from the EGG Consortium40, and (2) the first GWAS for AN9 
comprising 1,033 AN cases and 3,733 paediatric controls from the Price Foundation 
Collaborative Group and the Children’s Hospital of Pennsylvania. Finally, we performed 
functional studies of the four genes nearest to the best cross-trait findings.
Materials and Methods
Look-up of ‘AN SNPs’ (GCAN) in GIANT GWAMA for BMI including sex-specific analyses
Our primary analysis is based on the in silico look-up of the 1000 best hits according to p-
value (SNPs in high linkage disequilibrium (LD) were not excluded) derived from the case-
control AN GWAMA10 in the large scale GWAMA of up to 322,135 individuals from the 
population-based GIANT meta-analysis for BMI13. In light of the aforementioned results for 
obesity risk alleles in the AN GWAMA10, we did not pursue the directional hypothesis that 
AN susceptibility/risk alleles are protective of obesity (i.e. are expected to be BMI 
lowering); as a consequence, we report two-sided tests. Secondarily, we performed sex-
stratified analyses for the best cross-trait SNPs in the BMI GWAMA13.
We estimated the percentage of AN GWAMA SNPs that met the same p-value threshold in 
the BMI GWAMA (Supplementary Figure S1). We estimated that the genetic overlap of 
BMI and AN can seemingly be demonstrated if the number of SNPs analyzed is larger than 
500, so that the 1000 SNPs we had chosen is justified. We decided against a computational 
derivation of an “optimal” cut-off as this could inflate the type I error rate. We did not aim 
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for a comprehensive assessment of the joint common SNP variation architecture of both 
traits.
Post hoc we performed analyses in the sub data sets of GIANT (a: full GWAS chip data on 
N~233,000; b: Metabochip on N~88,000) to analyze if the observed effects are confirmed 
for each sub data set.
Look-up of ‘BMI SNPs’ in GWAMA for AN susceptibility (GCAN)
We performed an in silico lookup of the 56 novel genome-wide significant ‘BMI SNPs’ 
detected by Locke et al.13 in the case-control AN GWAMA (GCAN10). Subsequently we 
also analyzed previously described SNPs for BMI, obesity, childhood obesity, and WHR 
(see supplementary Tables). A total of 2,916 quality controlled genotypes of controls were 
included in both GCAN and GIANT (n=1,437 NBS-WTCCC National Blood Service 
donors and n=1,479 British 1958 birth cohort-WTCCC). Balancing between consistency 
(i.e. running our analyses on the same data sets as those published) and the necessity of 
sample independence, we rendered a re-analysis excluding these overlapping samples 
unnecessary.
Subsequent look-ups in independent GWAS data sets
We performed a look-up of the best cross-trait SNPs in GWAMA data of the EGG 
Consortium40 consisting of 5,530 obese children and adolescents (BMI ≥ 95th percentile) 
and 8,318 controls (BMI < 50th percentile). Data on the childhood obesity trait has been 
contributed by the EGG Consortium and was downloaded from www.egg-consortium.org40. 
An additional look-up of the best cross-trait SNPs from GCAN and GIANT was performed 
in the first GWAS for AN9 consisting of 1,033 AN cases and 3,733 paediatric control 
subjects of European ancestry; five SNPs were available.
Written informed consent to take part in genetic association studies was given by all 
participants and in case of minors by their parents. Studies were approved by the respective 
institutional review boards or ethics committees and conducted in accordance with The 
Declaration of Helsinki9,10,13,40.
Statistical analyses
We performed two main analyses and one stratified analysis nested within the first main 
analysis focussing on European-descent individuals of two GWAMAs. The GWAMA for 
AN10 was performed as fixed-effect meta-analysis based on single-SNP case-control 
association analyses under an additive genetic model with control for population 
stratification at the discovery data set level. Similarly, the GWAMA for BMI variation13 also 
worked with a fixed-effect meta-analysis based on discovery data set results obtained under 
a linear regression model adjusted for age, age2, sex, and study-specific covariates including 
control for population stratification effects. For the first main analysis, we looked-up the 
1000 SNPs of the GWAMA for AN10 with the lowest p-values (discovery p-values from 
5.56×10−22 to 4.79×10−4, of note: the SNP with the lowest p-value in the initial discovery 
GWAS for AN was not confirmed by genotyping in the replication sample10) in the 
GWAMA for BMI13. We applied a conservative Bonferroni-correction to the uncorrected p-
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values of the GWAMA for BMI to address multiple testing (see Table 1 and Supplementary 
Tables), and accordingly regarded all associations as significant which met a nominal p-
value ≤ 5×10−5 (Table 1). For the SNPs with significant associations in the GWAMA for 
BMI, we also report the results of sex-stratified sensitivity analyses (Table 1). For the second 
main analysis, we performed a look-up of the 97 BMI loci in the GWAMA for AN. The 
direction of effect was evaluated only for SNPs with a nominal p-value ≤ 0.05.
Post hoc we also analyzed genome-wide significant loci for BMI, obesity, childhood obesity 
not originally described in Locke et al.13 (reviewed in 41) and 68 genome-wide significant 
loci for waist-hip ratio (WHR) derived from a European GWAMA primary analysis 
(GIANT21) in the GWAMA for AN (GCAN10).
Animals and diet—Unless stated otherwise, male C57BL/6J mice were fed ad libitum 
with either a standard chow diet (Harlan Teklad LM-485; 5.6% kcal fat) or a high-fat diet 
(D12331; Research Diets, New Brunswick, NJ; 58% kcal fat). The mice had free access to 
water and were maintained under constant ambient conditions (22 ± 1°C, constant humidity, 
12h/12h light/dark cycle). All animal studies were performed in Cincinnati, OH, USA and 
were approved by the Animal Ethics Committee of Cincinnati, OH, USA.
Gene expression analyses—To assess effects on fasting and re-feeding, hypothalamic 
gene expression was profiled in male 27/28 week old C57BL/6J mice fed either ad libitum 
with a regular chow diet, or which had been fasted for 12h, 24h, or 36h, or which had been 
fasted for 36h and then re-fed for 6h using either a fat-free diet or a high-fat diet (N=6–8 
mice per group). The use of existing ex vivo material is in agreement with the US and 
German guidelines of the Animal Welfare Committee to restrict animal experiments to an 
absolutely necessary minimum. Target genes were amplified using the ViiA 7 real-time PCR 
system (Life Technologies; Darmstadt, Germany); results were normalized to the 
housekeeping gene hypoxanthine guanine phosphoribo-syltransferase 1 (HPRT). The used 
primer sequences were CTBP2-F: 3′-TACCACACCATCACCCTCAC -5′; CTBP2-R: 3′-
TGTGGCAGACTGTCGAATCT-5′; CCNEI-F:3′-AGCCTCGGAAAATCAGACCA-5′; 
CCNEI-R: 3′-CTTCGCACACctccattagc-5′, CARF-F: 3′-
GTGGACGACAGATAGTGGGA-5′; CARF-R: 3′-GGAGAGGAGAGTCTTGGCTG-5′; 
NBEAL1-F: 3′-AGGAGAAGGAAATGGCTGATCA-5′, and NBEAL1-R: 3′-
TCCACTGTGAGAGAAGCTGG-5′. Data represent means ± SEM. *P<0.05, **P<0.01, 
based on a one-way ANOVA with Dunnett’s Multiple Comparison post-hoc test.
To additionally assess the effects of a high fat diet on hypothalamic expression of Nbeal1 
and Ctbp2 was assessed in age matched male C57BL/6J mice fed either a regular chow diet 
(body weight 32.69g ± 0.45g) or a high-fat diet (body weight 54.72g ± 1.25g; N=7–8 mice 
per group). Data represent means ± SEM.
In silico analyses—Expression patterns and known variants in the coding regions 
(missense, nonsense and frameshift) were analyzed in silico (http://www.genecards.org/; 
http://exac.broadinstitute.org/about).
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Results
Association of AN risk SNPs with increased BMI
We detected association (p-values < 5×10−5, Bonferroni corrected p < 0.05) at three 
independent chromosomal loci in the BMI GWAMA (chromosome 2: four SNPs in linkage 
disequilibrium [LD], r2 ≥ 0.819, D′ = 1; chromosome 10: three SNPs, r2 ≥ 0.363, D′ ≥ 
0.728; and chromosome 19: two SNPs, r2 = 1, D′ = 1); the lowest p-value (rs1561589, 
2.47×10−6, pcorrected = 0.0025) was observed at the chromosome 10 locus (Table 1). Within 
the GIANT13 data we post hoc also analyzed the data sets separately for (a) full GWAS chip 
data (HapMap imputed) on N~233,000 and (b) Metabochip on N~88,000 (Supplementary 
Table S1). Both independent data sets confirmed the association of the nine SNPs.
The nearest genes to these nine SNPs ordered from lowest to highest p-values are: (1) 
chromosome 10: CTBP2 (C-terminal binding protein 2 gene); (2) chromosome 19: CCNE1 
(cyclin E1 gene); (3) chromosome 2: CARF (calcium responsive transcription factor gene) 
and (4) NBEAL1 (neurobeachin-like 1 gene). The third chromosomal locus included two 
genes, because the four SNPs are located in a region with high linkage disequilibrium 
(lowest LD for the four SNPs: r2 ≥ 0.819, D′ = 1). Interestingly, for all SNPs, the AN risk 
alleles were consistently associated with increased BMI (Table 1).
Sex-specific analyses for the best cross-trait SNPs (Table 1) revealed that the chromosome 
10 association signal was primarily driven by females. Again, post hoc sex-specific analyses 
in the sub data sets of GIANT (a: full GWAS chip data on N~233,000; b: Metabochip on 
N~88,000; supplementary Table S1) confirmed the larger effect in females for the best locus.
Further look-ups
Because AN typically manifests during adolescence, we analyzed the identified SNPs in the 
EGG Consortium data set40, which includes only children and adolescents. The lookup of 
the nine cross-trait SNPs (Table 1) did not reveal significant findings at the five SNPs 
available (p-values from 0.0916 at rs11245456 to 0.6075 at rs1561589). However, the 
direction of effect was the same between AN risk and early onset extreme obesity in all five 
SNPs.
The look-up of the nine cross-trait SNPs in the first GWAS for AN9 comprising 1,033 AN 
cases and 3,733 paediatric controls (five SNPs were available, each locus was represented) 
showed nominally significant results for two SNPs at chromosome 2 (rs17406900, nominal 
p = 0.03; rs7573079, nominal p = 0.04), our second best locus. However, for these SNPs the 
direction of effect was opposite to the effect in GCAN.
Association of ‘BMI SNPs’ with AN
The look-up of the ‘BMI SNPs’ in the AN GWAMA did not reveal (Bonferroni-corrected 
for 97 SNPs) significant results (Supplementary Tables S2–S4). Similarly, post hoc lookups 
of additional genome-wide significant loci for BMI, obesity, childhood obesity41 
(Supplementary Table S5) and WHR21 (Supplementary Table S6) in the GWAMA for AN 
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(GCAN10) did not reveal statistically significant findings after correction for multiple 
testing.
In silico analyses
All four genes located at the three identified loci are widely expressed in brain tissues, 
including the hypothalamus (http://www.genecards.org/). A spectrum of different, 
potentially functionally relevant variants (missense, nonsense and frameshift) was detected 
for all four genes (Supplementary Table S7).
Mouse model
Gene expression profiling of Ctbp2, Ccne1, Carf, Nbeal1 and in male C57BL/6J mice 
revealed that hypothalamic expression of both Ctbp2 and Nbeal1 was decreased by fasting 
(one-way ANOVA p<0.05 for both targets; Figure 1). Notably, hypothalamic expression of 
Ctbp2 and Nbeal1 remained decreased after 36h fasting followed by 6h re-feeding with 
either a fat-free diet or a high-fat diet relative to control mice fed ad libitum (Figure 1). In 
line with the down-regulation of hypothalamic expression of Ctbp2 and Nbeal1 in response 
to nutrient availability, expression of Ctbp2 was increased in diet-induced obese compared to 
age-matched lean control mice (p < 0.01; Figure 2); for Nbeal1 we noted a trend for 
increased expression in obese compared to lean mice (p = 0.070; Figure 2).
Discussion
Among the 1000 SNPs with the lowest p-values in the GCAN GWAMA for AN10 we 
identified nine SNPs in three chromosomal regions with significant p-values in the currently 
largest GWAMA for BMI variation13 using a conservative Bonferroni correction.
The relevance of these three loci is uncertain, because none of the nine SNPs have 
previously been identified for either AN or BMI/obesity or other psychiatric disorders. Two 
NBEAL1 SNPs (intronic and 3′UTR, rs16839626, rs6733725; no detectable LD to the SNPs 
identified here; http://www.broadinstitute.org/mpg/snap/ldsearchpw.php) had been detected 
in a GWAS for obesity related traits in 815 Hispanic children from 263 families42. Nominal 
associations (not genome-wide significant) for energy storage and fat mass deposition (p = 
2×10−7), fat mass change (4×10−7) and weight change (3×10−6) were shown42. Central 
(including hypothalamic) expression of all four genes was detected. We did not detect 
association of the previously published GWAMA SNPs for BMI, (childhood) obesity, or 
WHR with AN (Supplementary Tables).
The following results do not readily substantiate the relevance of our association findings: a) 
The analysis of the five out of nine available cross-trait SNPs in 5,530 obese children and 
adolescents (BMI ≥ 95th percentile) versus 8,318 controls (BMI < 50th percentile) from the 
EGG Consortium40 did not reveal significant findings. However, for all available SNPs the 
direction of effect was identical to that observed in the GIANT GWAMA. Because the EGG 
Consortium GWAMA is substantially smaller than the recent GIANT approach13, true 
signals may not have been detectable. b) The look-up of the same cross-trait SNPs in the 
first GWAS for AN9 did not support our findings. This might partly be explained by the 
lower sample size in the analysis of the Price Foundation Collaborative Group and 
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Children’s Hospital of Pennsylvania samples9 (1,033 AN cases and 3,733 paediatric 
controls) compared to the latest GWAS10 (2,907 cases with AN and 14,860 controls). In 
conclusion, we cannot exclude that our detected associations for the nine SNPs represent 
false positive associations.
The following lines of evidence do however support that we have indeed detected SNPs 
associated with both AN and obesity: The identification of the three loci with nominal p-
values in the range of 10−5 to 10−6 for association with BMI is quite unexpected. 
Accordingly, at least one and maximally all three loci are involved in body weight 
regulation; the same potentially holds true for AN. If this assumption is correct, future larger 
GWAMAs for both AN and BMI/obesity will pick up the respective loci. It is also of interest 
that all risk alleles were directionally consistent for AN risk and higher BMI. This is 
especially unexpected as (a) patients with AN do not have an elevated premorbid BMI33; (b) 
BMI-values of followed up patients only infrequently exceed the cutoff for overweight (BMI 
≥ 25 kg/m2)36 and (c) LD-score regression analyses revealed a negative genetic correlation 
between AN and obesity30. It is unlikely that the overlap between the AN (controls) and 
GIANT GWAMAs explains our results.
Sex-specific analyses
We also performed look-ups in sex-stratified analyses for the best cross-trait SNPs in the 
BMI GWAMA, because (i) AN predominantly occurs in females38,39 and (ii) sex-specific 
analyses rendered BMI loci that had not been picked up by sex-combined analyses13. We 
found that the three AN risk SNPs at the chromosome 10 locus with the lowest p-values in 
the BMI GWAMA (sex-combined) mainly originated from the female participants (Table 1). 
This finding provides additional indirect evidence that particularly this locus is involved in 
both AN and body weight regulation in females mainly.
Animal model
The hypothalamic expression data obtained in male mice clearly substantiate that the 
detected associations at two loci may indeed represent true positive findings. The cDNA of 
the fasting/re-feeding experiment described in this manuscript is commonly used in the 
Müller/Tschöp lab to assess regulation of target genes. Whereas unfortunately there is no 
documentation on the total number of previously analyzed targets, it can be confirmed that 
only few of the previously analyzed genes have been found to be differentially regulated 
under the conditions reported here (e.g. 43). Expression of Ctbp2, whose locus represented 
our strongest association signal (Table 1), proved to be inversely regulated by fasting and 
diet induced obesity. Thus, hypothalamic gene expression was reduced for this gene and 
additionally in fasted (12, 24 or 36 h) mice; this down-regulation persisted 6 hours after 
renewed access to adlibitum feeding (re-feeding for 6 h with either a high-fat diet or a fat-
free diet). Genes, whose expression is down-regulated in fasting, are usually anorexigenic 
(e.g., leptin44,45), while expression of orexigenic genes (e.g., ghrelin46) is increased in 
fasting. Hence it is likely that both Ctbp2 and Nbeal1 have an anorexigenic effect. In 
accordance with this assumption, both genes were up-regulated in diet induced obesity 
(DIO; Figure 2).
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BDNF signalling
It is of interest to point out that the two genes CTBP2 and CARF are involved in BDNF 
signaling pathways47–63. The leptinergic-melanocortinergic-BDNF pathway includes genes 
with known genetic variation underlying both monogenic and polygenic obesity64. Multiple 
SNPs near BDNF are genome-wide significantly associated with obesity (e.g. 13,65). 
Evidence for an involvement of BDNF in AN stems from studies on (a) animal models, (b) 
genetics, and (c) serum or brain levels of BDNF. However, some of the data are equivocal. In 
more detail: (a) in animal models the central infusion of BDNF induces weight loss66,67. 
The suppressive effects of BDNF on feeding behavior and body weight are mediated by 
corticotropin-releasing factor (CRF) and hypothalamic neuronal histamine in mice68. BDNF 
signaling is altered by reduced BDNF expression in the hippocampus, in activity-based 
anorexia in mice69 and in immobilization stress induced anorexia in rats70. Deletion of the 
Bdnf gene in the PVH resulted in hyperphagia, reduced locomotor activity, impaired 
thermogenesis, and severe obesity. Additionally, in response to cold exposure BDNF 
expression in the PVH was increased71. (b) Association of variation in BDNF with AN was 
shown by some but not all studies72–84. For the widely studied BDNF Val66Met variant, a 
recent meta-analysis showed no association of the infrequent 66Met allele with AN82. (c) 
Decreased serum and brain levels of BDNF had unequivocally been reported in patients with 
AN66,85–100. This was recently confirmed in a meta-analysis97. While only one study has 
suggested an interaction between CTBP2 and BDNF47, the interaction of CARF and BDNF 
has been substantiated in numerous studies (see above). Thus, again as BDNF might be 
involved in both AN and obesity27,101,102 this gene is biologically highly plausible.
In the following we provide additional information on the genes located nearest to the three 
loci identified via the nine SNPs starting with the chromosome harboring the SNPs with the 
lowest p-values:
Chromosome 10—The three intronic SNPs in the CTBP2 gene (C-terminal binding 
protein 2) show the lowest p-values in our BMI GWAMA13 look-up (Table 1); as stated 
above the effect is almost only due to females. The two alternative CTBP2 transcripts lead to 
two distinct proteins, one of which is a transcriptional repressor, while the other is a major 
component of synaptic ribbons, a specialized form of synapses. A NAD+ binding domain is 
common to both isoforms. There is evidence that the gene/protein is involved in brown 
adipose tissue function and regulation103–109. Ctbp2 knock-out mice displayed abnormal 
phenotypes in the cardiovascular and central nervous systems, in addition to having effects 
on embryogenesis, growth/size/body, and mortality/aging (http://www.informatics.jax.org/
allele/ MGI:2183646110). Recently, a miRNA that was up-regulated during the development 
of obesity in mice (miR-342-3p) was described to promote a suppressing effect on 
CtBP2111, again underscoring the relevance of the gene for weight regulation.
Chromosome 19—The cyclin E1 gene (CCNE1) identified via the two SNPs 5′ to this 
gene encodes a protein that belongs to the highly conserved cyclin family. Cyclins act as (i) 
regulators of specific kinases and (ii) contribute to the coordination of mitotic events. In 
many tumors overexpression of this gene has been observed112. It was recently shown that 
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proliferation of 3T3-L1 preadipocytes promoted by recombinant myostatin increased 
expression of proliferation related genes (e.g. cyclin E1 by 20.5 %113).
Chromosome 2—The third chromosomal locus includes two genes, because the four 
SNPs are located in a region with high linkage disequilibrium (lowest LD for the four SNPs: 
r2 ≥ 0.819, D′ = 1). Three of the SNPs are located in an intron, one is 5′ to NBEAL1 (Table 
1): (1) The calcium-response factor gene (CARF or as an alias name amyotrophic lateral 
sclerosis 2 (juvenile) chromosome region, candidate 8 gene: ALS2CR8) acts as a 
transcriptional activator that mediates the calcium- and neuron-selective induction of BDNF 
expression52. Lack of Carf (Als2cr8) in knock-out mice results in deficits associated with 
learning and memory56. Functionally relevant recessive mutations in the gene have been 
described in patients with amyotrophic lateral sclerosis 2 (ALS2114).
In sum, in a cross-trait analysis for genetic loci involved in AN risk and increased BMI three 
chromosomal loci with potential relevance for both traits were detected. Apart from the 
identification of these loci, their role in both AN and body weight regulation was particularly 
substantiated by ex vivo data of mouse models for fasting and DIO suggesting an anorexic 
role of CTBP2 and NBEAL1, by the sex specific results for CTBP2 and the finding that 
CTBP2 and CARF are involved in BDNF regulation. Further in depth molecular genetic and 
biological analyses are essential to understand the relevance of these loci and the genes they 
contain in the etiology of AN and in body weight regulation/obesity. The association of AN 
alleles with increased BMI might imply that a specific genetic variant (allele) can either 
increase or decrease BMI depending on presence or absence of additional factors with an 
influence of the body weight (e.g. occurrence of an eating disorder), or the variant 
predisposes to dysregulation and other genes or environmental factors determine its 
direction). If true, this general concept has implications for gene mapping approaches in 
genetic epidemiology calling for more hypothesis-driven stratified analyses. A spectrum of 
different variants (missense, nonsense and frameshift) has been described for the four genes 
(Supplementary Table 7), so that a mutation screen in these genes in study groups of patients 
with AN or extreme obesity is warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Hypothalamic expression of Ctbp2 (a), Ccne1 (b), Carf (c), Nbeal1 (d), or in response to 
fasting for 12, 24 or 36 h, and after re-feeding for 6 h with either a high-fat diet (HFD) or a 
fat-free diet (FFD, N = 6–8 mice per group) (c). *P<0.05, **P<0.01, based on a one-way 
ANOVA with Dunnett’s Multiple Comparison post-hoc test
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Figure 2. 
Hypothalamic expression of Ctbp2 and Nbeal1 in diet induced obesity (DIO) as compared to 
age-matched lean control mice.
Hinney et al. Page 22
Mol Psychiatry. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hinney et al. Page 23
Ta
bl
e 
1
N
in
e 
of
 th
e 
10
00
 S
N
Ps
 w
ith
 th
e 
lo
w
es
t p
-v
al
ue
s i
n 
a 
G
W
A
S 
fo
r A
N
 ri
sk
 (G
CA
N9
) a
re 
ass
oc
iat
ed
 w
ith
 in
cre
ase
d B
M
I (
GI
AN
T1
1 ,
 
w
ith
 B
on
fe
rro
ni
-
co
rr
ec
te
d 
P 
< 
0.
05
 si
gn
ifi
ca
nc
e;
 so
rte
d 
ac
co
rd
in
g 
to
 th
e 
no
m
in
al
 p
-v
al
ue
s f
or
 in
cr
ea
se
d 
BM
I i
n 
al
l G
IA
N
T 
pa
rti
ci
pa
nt
s)
C
hr
o
m
o
so
m
e/
po
sit
io
n
SN
P
n
ea
re
st
 g
en
e(s
)
Lo
ca
tio
n
R
an
k 
in
 A
N
 
G
W
A
S
A
N
 e
ffe
ct
 
a
lle
le
/
fr
eq
ue
nc
y 
in
 A
N
 
ca
se
s
O
dd
s R
at
io
 (S
E)
p-
va
lu
e 
fo
r 
A
N
 ri
sk
Fr
eq
ue
nc
y 
o
f A
N
 
re
fe
re
n
ce
 
a
lle
le
 fo
r 
BM
I
β (
se)
 fo
r 
BM
I 
fo
r 
re
fe
re
n
ce
 
a
lle
le
N
om
in
al
 
p-
va
lu
e 
fo
r 
in
cr
ea
se
d 
BM
I:
 a
ll 
fe
m
al
e/
m
a
le
Bo
nf
er
ro
n
i c
or
re
ct
ed
 p
-v
a
lu
ea
D
ir
ec
tio
n 
o
f e
ffe
ct
b 
+
/−
10
/1
26
68
56
63
rs
15
61
58
9
CT
BP
2
In
tro
n
20
1
A
 / 
0.
33
1.
14
 (0
.04
)
7.
74
 ×
 1
0−
05
A
 / 
0.
34
0.
01
57
 (0
.00
33
)
2.
47
 ×
 
10
−
06
3.
45
 ×
 
10
−
07
 
/ 
0.
04
3
0.
00
25
+
10
/1
26
68
11
70
rs
12
77
16
27
CT
BP
2
In
tro
n
19
0
G
 / 
0.
75
0.
87
 (0
.03
)
7.
28
 ×
 1
0−
05
G
 / 
0.
74
−
0.
01
62
 (0
.00
35
)
4.
25
 ×
 
10
−
06
5.
8 
× 
10
−
06
 
/ 
0.
02
2
0.
00
43
+
10
/1
26
67
40
64
rs
11
24
54
56
CT
BP
2
In
tro
n
17
7
C 
/ 0
.7
5
0.
87
 (0
.03
)
6.
79
 ×
 1
0−
05
C 
/ 0
.7
5
−
0.
01
71
 (0
.00
37
)
4.
58
 ×
 
10
−
06
1.
03
 ×
 
10
−
05
 
/ 
0.
00
9
0.
00
46
+
19
/3
49
78
66
2
rs
17
51
36
13
CC
NE
1
D
ist
an
t 5
′
40
9
T 
/ 0
.7
0
0.
88
 (0
.03
)
0.
00
02
T 
/ 0
.6
7
−
0.
01
5 
(0.
00
33
)
5.
41
 ×
 
10
−
06
6.
4 
× 
10
−
03
 
/ 
1.
24
 ×
 
10
−
05
0.
00
54
+
2/
20
34
92
44
7
rs
17
40
69
00
CA
RF
In
tro
n
70
9
A
 / 
0.
48
0.
90
 (0
.03
)
0.
00
03
A
 / 
0.
49
−
0.
01
34
 (0
.00
31
)
1.
08
 ×
 
10
−
05
1.
8 
× 
10
−
04
 
/ 
2.
27
 ×
 
10
−
03
0.
01
08
+
2/
20
36
39
25
7
rs
75
93
91
7
N
BE
A
L1
In
tro
n
44
4
A
 / 
0.
46
0.
89
 (0
.03
)
0.
00
02
A
 / 
0.
46
−
0.
01
31
 (0
.00
31
)
2.
48
 ×
 
10
−
05
9.
54
 ×
 
10
−
05
 
/ 
9.
39
 ×
 
10
−
03
0.
02
48
+
Mol Psychiatry. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hinney et al. Page 24
C
hr
o
m
o
so
m
e/
po
sit
io
n
SN
P
n
ea
re
st
 g
en
e(s
)
Lo
ca
tio
n
R
an
k 
in
 A
N
 
G
W
A
S
A
N
 e
ffe
ct
 
a
lle
le
/
fr
eq
ue
nc
y 
in
 A
N
 
ca
se
s
O
dd
s R
at
io
 (S
E)
p-
va
lu
e 
fo
r 
A
N
 ri
sk
Fr
eq
ue
nc
y 
o
f A
N
 
re
fe
re
n
ce
 
a
lle
le
 fo
r 
BM
I
β (
se)
 fo
r 
BM
I 
fo
r 
re
fe
re
n
ce
 
a
lle
le
N
om
in
al
 
p-
va
lu
e 
fo
r 
in
cr
ea
se
d 
BM
I:
 a
ll 
fe
m
al
e/
m
a
le
Bo
nf
er
ro
n
i c
or
re
ct
ed
 p
-v
a
lu
ea
D
ir
ec
tio
n 
o
f e
ffe
ct
b 
+
/−
2/
20
35
82
15
7
rs
11
69
13
51
N
BE
A
L1
D
ist
an
t 5
′
41
2
A
 / 
0.
46
0.
89
 (0
.03
)
0.
00
02
A
 / 
0.
46
−
0.
01
26
 (0
.00
31
)
3.
57
 ×
 
10
−
05
1.
98
 ×
 
10
−
04
 
/ 
8.
21
 ×
 
10
−
03
0.
03
57
+
19
/3
49
88
69
3
rs
81
02
13
7
CC
NE
1
D
ist
an
t 5
′
24
8
T 
/ 0
.7
0
0.
88
 (0
.03
)
9.
45
 ×
 1
0−
05
T 
/ 0
.6
7
−
0.
01
69
 (0
.00
41
)
3.
76
 ×
 
10
−
05
0.
00
6 
/ 
2.
46
 ×
 
10
−
04
0.
03
76
+
2/
20
36
35
79
6
rs
75
73
07
9
N
BE
A
L1
In
tro
n
40
1
G
 / 
0.
46
0.
89
 (0
.03
)
0.
00
02
G
 / 
0.
46
−
0.
01
24
 (0
.00
31
)
4.
61
 ×
 
10
−
05
2.
80
 ×
 
10
−
04
 
/ 
0.
00
8
0.
04
61
+
a p
rim
ar
y 
an
al
ys
is,
 se
x
-c
o
m
bi
ne
d,
 c
or
re
ct
io
n 
fo
r 1
,0
00
 te
sts
b D
ire
ct
io
n 
of
 e
ffe
ct
: +
 th
e 
ef
fe
ct
/ri
sk
 a
lle
le
 fo
r i
nc
re
as
ed
 B
M
I a
nd
 A
N
 ri
sk
 a
re
 id
en
tic
al
; −
 th
e 
ef
fe
ct
/ri
sk
 a
lle
le
 fo
r i
nc
re
as
ed
 B
M
I a
nd
 A
N
 ri
sk
 a
re
 n
ot
 id
en
tic
al
.
G
en
e a
bb
re
v
ia
tio
ns
 (a
lph
ab
eti
ca
lly
): A
LS
2C
R8
 
(am
yo
tro
ph
ic 
lat
era
l s
cle
ros
is 
2 (
juv
en
ile
) c
hro
mo
so
me
 re
gi
on
, c
an
di
da
te
 8
), C
AR
F (
Ca
lci
um
 R
esp
on
siv
e 
Tr
an
sc
rip
tio
n 
Fa
ct
or
); 
CC
NE
1 
(cy
cl
in
 E
1),
 
CT
BP
2 
(C
-te
rm
ina
l b
ind
ing
 pr
ote
in 
2),
 N
BE
A
L1
 
(ne
uro
be
ac
hin
-li
ke
 1
)
Mol Psychiatry. Author manuscript; available in PMC 2017 August 01.
